[go: up one dir, main page]

WO2001059064A3 - Acides nucleiques, proteines et anticorps - Google Patents

Acides nucleiques, proteines et anticorps Download PDF

Info

Publication number
WO2001059064A3
WO2001059064A3 PCT/US2001/001342 US0101342W WO0159064A3 WO 2001059064 A3 WO2001059064 A3 WO 2001059064A3 US 0101342 W US0101342 W US 0101342W WO 0159064 A3 WO0159064 A3 WO 0159064A3
Authority
WO
WIPO (PCT)
Prior art keywords
bladder
polypeptides
antibodies
polynucleotides
treating
Prior art date
Application number
PCT/US2001/001342
Other languages
English (en)
Other versions
WO2001059064A2 (fr
Inventor
Craig A Rosen
Steven C Barash
Steven M Ruben
Original Assignee
Human Genome Sciences Inc
Craig A Rosen
Steven C Barash
Steven M Ruben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Craig A Rosen, Steven C Barash, Steven M Ruben filed Critical Human Genome Sciences Inc
Priority to EP01912656A priority Critical patent/EP1252176A2/fr
Publication of WO2001059064A2 publication Critical patent/WO2001059064A2/fr
Publication of WO2001059064A3 publication Critical patent/WO2001059064A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne de nouveaux polynucléotides liés à la vessie, les polypeptides codés par ces polynucléotides appelés ici collectivement 'antigènes de la vessie', ainsi que des anticorps fixant de manière immunospécifique ces polypeptides, et l'utilisation de ces polynucléotide, antigènes et anticorps de la vessie pour détecter, traiter, prévenir et/ou pronostiquer des troubles du système vésical, notamment, de façon non exhaustive, la présence d'un cancer de la vessie et de métastases de la vessie. Plus spécifiquement, l'invention concerne des molécules d'acides nucléiques de la vessie isolées codant les nouveaux polypeptides de la vessie. L'invention a trait à de nouveaux polypeptides de la vessie ainsi qu'à des anticorps se fixant à ces polypeptides. L'invention a également trait à des vecteurs, des cellules hôtes ainsi que des méthodes de recombinaison et de synthèse permettant de produire des polynucléotides, des polypeptides et/ou des anticorps de la vessie. L'invention concerne aussi des méthodes diagnostiques et thérapeutiques utiles pour diagnostiquer, traiter, prévenir et/ou pronostiquer des troubles liés à la vessie, notamment le cancer de la vessie ainsi que des méthodes thérapeutiques de traitement de ces troubles. L'invention porte également sur des méthodes de criblage permettant d'identifier des agonistes et des antagonistes de polynucléotides et de polypeptides de l'invention. Enfin, l'invention concerne des méthodes et/ou des compositions permettant d'inhiber ou de stimuler la production et/ou la fonction des polypeptides de l'invention.
PCT/US2001/001342 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps WO2001059064A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP01912656A EP1252176A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps

Applications Claiming Priority (235)

Application Number Priority Date Filing Date Title
US17906500P 2000-01-31 2000-01-31
US60/179,065 2000-01-31
US18062800P 2000-02-04 2000-02-04
US60/180,628 2000-02-04
US18466400P 2000-02-24 2000-02-24
US60/184,664 2000-02-24
US18635000P 2000-03-02 2000-03-02
US60/186,350 2000-03-02
US18987400P 2000-03-16 2000-03-16
US60/189,874 2000-03-16
US19007600P 2000-03-17 2000-03-17
US60/190,076 2000-03-17
US19812300P 2000-04-18 2000-04-18
US60/198,123 2000-04-18
US20551500P 2000-05-19 2000-05-19
US60/205,515 2000-05-19
US20946700P 2000-06-07 2000-06-07
US60/209,467 2000-06-07
US21488600P 2000-06-28 2000-06-28
US60/214,886 2000-06-28
US21513500P 2000-06-30 2000-06-30
US60/215,135 2000-06-30
US21664700P 2000-07-07 2000-07-07
US21688000P 2000-07-07 2000-07-07
US60/216,647 2000-07-07
US60/216,880 2000-07-07
US21748700P 2000-07-11 2000-07-11
US21749600P 2000-07-11 2000-07-11
US60/217,487 2000-07-11
US60/217,496 2000-07-11
US21829000P 2000-07-14 2000-07-14
US60/218,290 2000-07-14
US22096400P 2000-07-26 2000-07-26
US22096300P 2000-07-26 2000-07-26
US60/220,963 2000-07-26
US60/220,964 2000-07-26
US22575900P 2000-08-14 2000-08-14
US22521400P 2000-08-14 2000-08-14
US22521300P 2000-08-14 2000-08-14
US22451900P 2000-08-14 2000-08-14
US22575800P 2000-08-14 2000-08-14
US22526700P 2000-08-14 2000-08-14
US22544700P 2000-08-14 2000-08-14
US22575700P 2000-08-14 2000-08-14
US22526600P 2000-08-14 2000-08-14
US22526800P 2000-08-14 2000-08-14
US22451800P 2000-08-14 2000-08-14
US22527000P 2000-08-14 2000-08-14
US60/225,267 2000-08-14
US60/224,519 2000-08-14
US60/225,759 2000-08-14
US60/225,757 2000-08-14
US60/225,758 2000-08-14
US60/225,266 2000-08-14
US60/225,214 2000-08-14
US60/225,270 2000-08-14
US60/225,447 2000-08-14
US60/224,518 2000-08-14
US60/225,268 2000-08-14
US60/225,213 2000-08-14
US22627900P 2000-08-18 2000-08-18
US60/226,279 2000-08-18
US22668100P 2000-08-22 2000-08-22
US22686800P 2000-08-22 2000-08-22
US22718200P 2000-08-22 2000-08-22
US60/226,681 2000-08-22
US60/226,868 2000-08-22
US60/227,182 2000-08-22
US22700900P 2000-08-23 2000-08-23
US60/227,009 2000-08-23
US22892400P 2000-08-30 2000-08-30
US60/228,924 2000-08-30
US22934400P 2000-09-01 2000-09-01
US22934300P 2000-09-01 2000-09-01
US22934500P 2000-09-01 2000-09-01
US22928700P 2000-09-01 2000-09-01
US60/229,287 2000-09-01
US60/229,344 2000-09-01
US60/229,345 2000-09-01
US60/229,343 2000-09-01
US22950900P 2000-09-05 2000-09-05
US22951300P 2000-09-05 2000-09-05
US60/229,513 2000-09-05
US60/229,509 2000-09-05
US23043800P 2000-09-06 2000-09-06
US23043700P 2000-09-06 2000-09-06
US60/230,437 2000-09-06
US60/230,438 2000-09-06
US23124300P 2000-09-08 2000-09-08
US23141400P 2000-09-08 2000-09-08
US23208100P 2000-09-08 2000-09-08
US23141300P 2000-09-08 2000-09-08
US23124200P 2000-09-08 2000-09-08
US23124400P 2000-09-08 2000-09-08
US23208000P 2000-09-08 2000-09-08
US60/231,414 2000-09-08
US60/231,243 2000-09-08
US60/232,081 2000-09-08
US60/231,413 2000-09-08
US60/232,080 2000-09-08
US60/231,244 2000-09-08
US60/231,242 2000-09-08
US23196800P 2000-09-12 2000-09-12
US60/231,968 2000-09-12
US23306500P 2000-09-14 2000-09-14
US23239900P 2000-09-14 2000-09-14
US23306400P 2000-09-14 2000-09-14
US23239800P 2000-09-14 2000-09-14
US23240000P 2000-09-14 2000-09-14
US23239700P 2000-09-14 2000-09-14
US23306300P 2000-09-14 2000-09-14
US23240100P 2000-09-14 2000-09-14
US60/233,065 2000-09-14
US60/232,398 2000-09-14
US60/233,063 2000-09-14
US60/232,399 2000-09-14
US60/232,400 2000-09-14
US60/233,064 2000-09-14
US60/232,401 2000-09-14
US60/232,397 2000-09-14
US23427400P 2000-09-21 2000-09-21
US23422300P 2000-09-21 2000-09-21
US60/234,223 2000-09-21
US60/234,274 2000-09-21
US23499800P 2000-09-25 2000-09-25
US23499700P 2000-09-25 2000-09-25
US60/234,998 2000-09-25
US60/234,997 2000-09-25
US23548400P 2000-09-26 2000-09-26
US60/235,484 2000-09-26
US23583600P 2000-09-27 2000-09-27
US23583400P 2000-09-27 2000-09-27
US60/235,834 2000-09-27
US60/235,836 2000-09-27
US23636700P 2000-09-29 2000-09-29
US23636800P 2000-09-29 2000-09-29
US23637000P 2000-09-29 2000-09-29
US23636900P 2000-09-29 2000-09-29
US23632700P 2000-09-29 2000-09-29
US60/236,327 2000-09-29
US60/236,369 2000-09-29
US60/236,368 2000-09-29
US60/236,367 2000-09-29
US60/236,370 2000-09-29
US23703800P 2000-10-02 2000-10-02
US23704000P 2000-10-02 2000-10-02
US23703900P 2000-10-02 2000-10-02
US23680200P 2000-10-02 2000-10-02
US23703700P 2000-10-02 2000-10-02
US60/237,040 2000-10-02
US60/237,037 2000-10-02
US60/237,038 2000-10-02
US60/236,802 2000-10-02
US60/237,039 2000-10-02
US23993500P 2000-10-13 2000-10-13
US23993700P 2000-10-13 2000-10-13
US60/239,935 2000-10-13
US60/239,937 2000-10-13
US24180800P 2000-10-20 2000-10-20
US24122100P 2000-10-20 2000-10-20
US24178700P 2000-10-20 2000-10-20
US24178500P 2000-10-20 2000-10-20
US24178600P 2000-10-20 2000-10-20
US24096000P 2000-10-20 2000-10-20
US24182600P 2000-10-20 2000-10-20
US24180900P 2000-10-20 2000-10-20
US60/240,960 2000-10-20
US60/241,221 2000-10-20
US60/241,826 2000-10-20
US60/241,786 2000-10-20
US60/241,785 2000-10-20
US60/241,787 2000-10-20
US60/241,808 2000-10-20
US60/241,809 2000-10-20
US24461700P 2000-11-01 2000-11-01
US60/244,617 2000-11-01
US24652500P 2000-11-08 2000-11-08
US24647700P 2000-11-08 2000-11-08
US24647500P 2000-11-08 2000-11-08
US24652700P 2000-11-08 2000-11-08
US24661100P 2000-11-08 2000-11-08
US24661000P 2000-11-08 2000-11-08
US24647600P 2000-11-08 2000-11-08
US24652800P 2000-11-08 2000-11-08
US24653200P 2000-11-08 2000-11-08
US24647400P 2000-11-08 2000-11-08
US24652600P 2000-11-08 2000-11-08
US60/246,524 2000-11-08
US60/246,476 2000-11-08
US60/246,610 2000-11-08
US60/246,526 2000-11-08
US60/246,475 2000-11-08
US60/246,528 2000-11-08
US60/246,527 2000-11-08
US60/246,477 2000-11-08
US60/246,474 2000-11-08
US60/246,611 2000-11-08
US60/246,532 2000-11-08
US60/246,523 2000-11-08
US60/246,478 2000-11-08
US60/246,609 2000-11-08
US60/246,613 2000-11-08
US60/246,525 2000-11-08
US60/249,214 2000-11-17
US60/249,211 2000-11-17
US60/249,300 2000-11-17
US60/249,299 2000-11-17
US60/249,245 2000-11-17
US60/249,265 2000-11-17
US60/249,217 2000-11-17
US60/249,218 2000-11-17
US60/249,210 2000-11-17
US60/249,297 2000-11-17
US60/249,213 2000-11-17
US60/249,215 2000-11-17
US60/249,208 2000-11-17
US60/249,244 2000-11-17
US60/249,212 2000-11-17
US60/249,264 2000-11-17
US60/249,209 2000-11-17
US60/249,207 2000-11-17
US60/249,216 2000-11-17
US60/250,160 2000-12-01
US60/250,391 2000-12-01
US60/256,719 2000-12-05
US60/251,988 2000-12-05
US60/251,030 2000-12-05
US60/251,479 2000-12-06
US60/251,990 2000-12-08
US60/251,856 2000-12-08
US60/251,868 2000-12-08
US60/251,989 2000-12-08
US60/251,869 2000-12-08
US60/254,097 2000-12-11
US60/259,678 2001-01-05

Publications (2)

Publication Number Publication Date
WO2001059064A2 WO2001059064A2 (fr) 2001-08-16
WO2001059064A3 true WO2001059064A3 (fr) 2002-03-14

Family

ID=27587117

Family Applications (48)

Application Number Title Priority Date Filing Date
PCT/US2001/001350 WO2001055350A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001349 WO2001054474A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001314 WO2001055310A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001343 WO2001055323A2 (fr) 2000-01-31 2001-01-17 Acides ncleiques, proteines et anticorps
PCT/US2001/001302 WO2001055304A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001339 WO2001055320A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001308 WO2001055364A2 (fr) 2000-01-31 2001-01-17 Acides nucléiques, protéines et anticorps
PCT/US2001/001340 WO2001055321A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001328 WO2001055316A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001325 WO2001055202A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001315 WO2001055311A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001351 WO2001055355A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001332 WO2001055318A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001317 WO2001055201A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001345 WO2001055325A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001330 WO2001055447A1 (fr) 2000-01-31 2001-01-17 Acides nucléiques, proteines et anticorps
PCT/US2001/001316 WO2001054473A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001301 WO2001055303A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001353 WO2001055206A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001337 WO2001055205A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001306 WO2001055307A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001309 WO2001055308A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001324 WO2001055314A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001352 WO2001055327A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001344 WO2001055324A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001322 WO2001055343A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001354 WO2001057182A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001336 WO2001055204A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001239 WO2001055301A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001312 WO2001054733A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001342 WO2001059064A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001321 WO2001055312A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001358 WO2001055163A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
PCT/US2001/001356 WO2001055173A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001313 WO2001055200A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001240 WO2001055302A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001311 WO2001055309A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001355 WO2001055207A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001338 WO2001055367A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et antigenes
PCT/US2001/001333 WO2001055448A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001341 WO2001055322A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001357 WO2001055208A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001359 WO2001055328A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001326 WO2001055315A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
PCT/US2001/001335 WO2001055319A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001327 WO2001055203A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001348 WO2001055368A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001310 WO2001055387A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps

Family Applications Before (30)

Application Number Title Priority Date Filing Date
PCT/US2001/001350 WO2001055350A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001349 WO2001054474A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001314 WO2001055310A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001343 WO2001055323A2 (fr) 2000-01-31 2001-01-17 Acides ncleiques, proteines et anticorps
PCT/US2001/001302 WO2001055304A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001339 WO2001055320A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001308 WO2001055364A2 (fr) 2000-01-31 2001-01-17 Acides nucléiques, protéines et anticorps
PCT/US2001/001340 WO2001055321A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001328 WO2001055316A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001325 WO2001055202A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001315 WO2001055311A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001351 WO2001055355A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001332 WO2001055318A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001317 WO2001055201A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001345 WO2001055325A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001330 WO2001055447A1 (fr) 2000-01-31 2001-01-17 Acides nucléiques, proteines et anticorps
PCT/US2001/001316 WO2001054473A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001301 WO2001055303A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001353 WO2001055206A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001337 WO2001055205A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001306 WO2001055307A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001309 WO2001055308A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001324 WO2001055314A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001352 WO2001055327A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001344 WO2001055324A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001322 WO2001055343A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001354 WO2001057182A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001336 WO2001055204A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001239 WO2001055301A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001312 WO2001054733A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps

Family Applications After (17)

Application Number Title Priority Date Filing Date
PCT/US2001/001321 WO2001055312A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001358 WO2001055163A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
PCT/US2001/001356 WO2001055173A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001313 WO2001055200A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001240 WO2001055302A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001311 WO2001055309A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001355 WO2001055207A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001338 WO2001055367A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et antigenes
PCT/US2001/001333 WO2001055448A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001341 WO2001055322A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001357 WO2001055208A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001359 WO2001055328A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001326 WO2001055315A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
PCT/US2001/001335 WO2001055319A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001327 WO2001055203A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001348 WO2001055368A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001310 WO2001055387A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps

Country Status (3)

Country Link
AU (16) AU2001241409A1 (fr)
CA (37) CA2393912A1 (fr)
WO (48) WO2001055350A1 (fr)

Families Citing this family (284)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6706262B1 (en) 1998-03-18 2004-03-16 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6960570B2 (en) 1998-03-18 2005-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
IL138930A0 (en) 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US6929938B2 (en) 2001-08-15 2005-08-16 Millennium Pharmaceuticals, Inc. 25501, a human transferase family member and uses therefor
US7141417B1 (en) 1999-02-25 2006-11-28 Thomas Jefferson University Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
EP1163252A4 (fr) * 1999-02-25 2004-04-07 Univ Jefferson Compositions, kits et procedes concernant le gene fez1 de l'homme, nouveau gene suppresseur des tumeurs
WO2000050458A1 (fr) * 1999-02-26 2000-08-31 Smithkline Beecham Corporation Clonage du recepteur 7tm (axor 17) du type p2y
JP2004506402A (ja) * 1999-03-23 2004-03-04 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド ４８のヒト分泌タンパク質
AU3330700A (en) 1999-03-29 2000-10-16 Tasuku Honjo Novel cytidine deaminase
CA2380550C (fr) 1999-08-12 2011-02-01 Urogenesys, Inc. Antigene transmembranaire lectine du type c exprime dans le cancer humain de la prostate et ses utilisations
EP1892249A1 (fr) * 1999-09-01 2008-02-27 Genentech, Inc. Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
US7083944B1 (en) * 1999-10-27 2006-08-01 Millennium Pharmaceuticals, Inc. Molecules of the card-related protein family and uses thereof
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US7005499B1 (en) * 1999-11-18 2006-02-28 Genentech, Inc. Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same
EP1878796A3 (fr) * 1999-11-30 2008-01-23 Genentech, Inc. Compositions et procédés pour le traitement de maladies liées au système immunitaire
EP1669371A3 (fr) * 1999-12-01 2006-06-21 Genentech, Inc. Composition et procédés de diagnostic de tumeurs
CN1300781A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽-人shc蛋白43和编码这种多肽的多核苷酸
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
IL150873A0 (en) 2000-01-26 2003-02-12 Agensys Inc 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
US6953682B2 (en) 2000-02-10 2005-10-11 Millennium Pharmaceuticals, Inc. Nucleic acid sequences encoding adenylate kinase, phospholipid scramblase-like, DNA fragmentation factor-like, phosphatidylserine synthase-like, and atpase-like molecules and uses therefor
US7078205B2 (en) 2000-02-17 2006-07-18 Millennium Pharmaceuticals, Inc. Nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, atpase molecules, acyltransferase molecules, pyridoxal-phosphate dependent enzyme molecules and uses therefor
US20020082212A1 (en) * 2000-07-20 2002-06-27 Millennium Pharmaceuticals, Inc. 7716, a novel human ATPase and uses therefor
US20020090705A1 (en) * 2000-07-14 2002-07-11 Rachel Meyers 62088, a novel human nucleoside phosphatase family member and uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
JP2003527860A (ja) * 2000-03-23 2003-09-24 イミューソル インコーポレイテッド Ｂｒｃａ−１制御因子およびその使用方法
WO2001073050A2 (fr) 2000-03-24 2001-10-04 Millennium Pharmaceuticals, Inc. 3714, 16742, 23546, et 13887 nouvelles molecules de proteine kinase et leurs utilisations
US20030198953A1 (en) * 2000-03-30 2003-10-23 Spytek Kimberly A. Novel proteins and nucleic acids encoding same
US7632929B2 (en) 2000-04-20 2009-12-15 The Board Of Trustees Of The University Of Arkansas Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof
AU5719501A (en) 2000-04-25 2001-11-07 Lexicon Genetics Inc Novel human kinase proteins and polynucleotides encoding the same
WO2001081586A2 (fr) * 2000-04-26 2001-11-01 Millennium Pharmaceuticals, Inc. 21657, deshydrogenase humaine a chaine courte et ses utilisations
US6808876B1 (en) * 2000-05-02 2004-10-26 Immusol, Inc. Cellular regulators of infectious agents and methods of use
US20030096313A1 (en) * 2000-05-12 2003-05-22 Burkhard Scharm Novel serine-threonine kinase-4
EP1158001B1 (fr) * 2000-05-26 2007-11-14 F. Hoffmann-La Roche Ag Un acide nucléique produit excessivement dans des cellules tumorales humaines, une protéine codée par ledit acide nucléique et un procédé de diagnose de tumeurs
EP1307545A2 (fr) * 2000-05-26 2003-05-07 Bayer Aktiengesellschaft Regulation de la serine/threonine kinase humaine analogue a p78
DE10027170A1 (de) * 2000-05-31 2001-12-13 Schering Ag Humanes PEM als Target für die Fertilitätskontrolle
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001093805A2 (fr) * 2000-06-02 2001-12-13 The Brigham & Women's Hospital, Inc. Fusion de genes jazf1 et jjaz1 dans des tumeurs stromatolithiques endometriales
AU6531101A (en) * 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6604901A (en) * 2000-06-05 2001-12-17 Bayer Aktiengesellschaft Regulation of human hm74-like g protein coupled receptor
EP1287029A2 (fr) * 2000-06-09 2003-03-05 Corixa Corporation Compositions et procedes pour la therapie et le diagnostic du cancer du colon
US6323016B1 (en) 2000-06-09 2001-11-27 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2001268435A1 (en) * 2000-06-15 2001-12-24 Millennium Pharmaceuticals, Inc. 23680, a novel human aminotransferase and uses therefor
WO2001096546A2 (fr) * 2000-06-16 2001-12-20 Incyte Genomics, Inc. Proteine-phosphatases
CA2709771A1 (fr) * 2000-06-23 2002-01-03 Genentech, Inc. Compositions et methode de diagnostic et de traitement des troubles mettant en cause l'angiogenese
EP1325114A2 (fr) * 2000-06-26 2003-07-09 Millennium Pharmaceuticals, Inc. 46619, une nouvelle synthase beta-cetoacyle et utilisations de cette derniere
EP1309684A2 (fr) * 2000-06-27 2003-05-14 Curagen Corporation Polynucleotides et polypeptides codes par ceux-ci
US7094587B2 (en) 2000-06-27 2006-08-22 Millennium Pharmaceuticals, Inc. 16002 Molecules and uses therefor
US6774223B2 (en) 2000-06-28 2004-08-10 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
WO2002002761A2 (fr) * 2000-06-30 2002-01-10 Millennium Pharmaceuticals, Inc. 57658, nouvelle uridine kinase humaine et utilisations correspondantes
AU2001273239A1 (en) * 2000-07-07 2002-01-21 Incyte Genomics, Inc. Transporters and ion channels
AU2001271843A1 (en) * 2000-07-07 2002-01-21 Incyte Genomics, Inc. Gtp-binding proteins
US6740751B2 (en) 2000-07-18 2004-05-25 Board Of Regents, The University Of Texas System Methods and compositions for stabilizing microtubules and intermediate filaments in striated muscle cells
US20030171324A1 (en) * 2000-07-18 2003-09-11 Shyam Ramakrishnan Regulation of human desc1-like serine protease
JP2004514420A (ja) * 2000-07-20 2004-05-20 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードする核酸
AU2001287629B2 (en) * 2000-07-25 2006-08-17 Merck Patent Gmbh Novel protein containing ring finger domaine R1P4
AU2001277202A1 (en) * 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ras/rerg protein and related reagents and methods of use thereof
WO2002008281A2 (fr) * 2000-07-26 2002-01-31 Stanford University Proteine bstp-cad et reactifs associes et methodes d'utilisation
US7335732B2 (en) 2000-08-01 2008-02-26 Genentech, Inc. PRO9799 polypeptides
EP1657254A3 (fr) * 2000-08-01 2006-06-07 Genentech, Inc. Polypeptide, acides nucléiques le codant, et leur utilisation pour le diagnostic du cancer
EP1315431A1 (fr) * 2000-08-02 2003-06-04 Millennium Pharmaceuticals, Inc. Membre de la famille du facteur de liberation du gtp humain (15368) et ses utilisations
JP2004527210A (ja) 2000-08-02 2004-09-09 ザ ジョンズ ホプキンス ユニバーシティー 内皮細胞発現パターンの評価法
US6924364B2 (en) 2000-08-04 2005-08-02 Zymogenetics, Inc. Human secreted protein, Zzp1
WO2002012285A2 (fr) 2000-08-10 2002-02-14 Board Of Regents, The University Of Texas System Suppresseur de tumeur car-1
EP1307566A2 (fr) * 2000-08-11 2003-05-07 MERCK PATENT GmbH Proteines mekk
EP1326985A1 (fr) * 2000-08-18 2003-07-16 MERCK PATENT GmbH Identification d'un gene d'acetyltransferase n-terminale humaine
WO2002016586A2 (fr) 2000-08-21 2002-02-28 Bristol-Myers Squibb Company Nouvel homologue d'adenosine deaminase
WO2002016587A2 (fr) * 2000-08-21 2002-02-28 Incyte Genomics, Inc. Proteines associees aux microtubules et tubulines
WO2002016579A2 (fr) * 2000-08-24 2002-02-28 Eli Lilly And Company Acides nucleiques, vecteurs, cellules hotes, polypeptides et utilisations de ces derniers
AU2001284176A1 (en) * 2000-08-28 2002-03-13 Astrazeneca Ab Molecules involved in the regulation of insulin in resistance syndrome (irs)
PT1313850E (pt) 2000-08-28 2008-11-18 Agensys Inc Ácido nucleico e proteína correspondente denominados 85p1b3 úteis no tratamento e na detecção de cancro
CA2420902A1 (fr) * 2000-08-28 2002-03-07 Craig A. Rosen 18 proteines humaines secretees
WO2002018552A2 (fr) * 2000-08-30 2002-03-07 Bayer Aktiengesellschaft Regulation d'enzyme humaine de type aminotransferase
WO2002018577A2 (fr) * 2000-08-30 2002-03-07 Millennium Pharmaceuticals, Inc. Nouveau facteur de terminaison du gtp humain 48921 et ses utilisations
AU2002210464A1 (en) * 2000-08-30 2002-03-13 Bayer Aktiengesellschaft Regulation of human aminotransferase-like enzyme
US20020091238A1 (en) * 2000-08-30 2002-07-11 Curtis Rory A.J. 54370, a novel human sulfate transporter and uses therefor
AU2001288600A1 (en) * 2000-08-31 2002-03-13 Millennium Pharmaceuticals, Inc. 62112, a novel human dehydrogenase and uses thereof
CA2421265A1 (fr) * 2000-09-05 2002-03-14 Incyte Genomics, Inc. Molecules utilisees a des fins diagnostiques et therapeutiques
MXPA03001930A (es) 2000-09-05 2003-06-19 Amgen Inc Moleculas pseudorreceptoras de factor de necrosis tumoral y uso de las mismas.
AU2001288999A1 (en) * 2000-09-08 2002-03-22 Millennium Pharmaceuticals, Inc. 38646, a guanine nucleotide exchange factor and uses therefor
US6372468B1 (en) 2000-09-14 2002-04-16 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US6391606B1 (en) * 2000-09-14 2002-05-21 Pe Corporation Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof
US20040048245A1 (en) * 2000-10-05 2004-03-11 Shimkets Richard A. Novel human proteins, polynucleotides encoding them and methods of using the same
AU2002220613A1 (en) * 2000-10-11 2002-04-22 Bayer Aktiengesellschaft Regulation of human cyclophilin-type peptidyl-prolyl cis-trans isomerase
AU2002211597A1 (en) * 2000-10-11 2002-04-22 Millennium Pharmaceuticals, Inc. 8843, a human dual specificity phosphatase family member and uses therefor
AU2002211715A1 (en) * 2000-10-12 2002-04-22 The Texas A And M University System Nucleic acid sequences encoding cmg proteins cmg proteins and methods for their use
EP1474528A4 (fr) * 2000-10-13 2006-06-14 Protein Design Labs Inc Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
US6531297B2 (en) * 2000-10-20 2003-03-11 Applera Corporation Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
AU2002249787A1 (en) 2000-10-25 2002-08-19 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
WO2002036781A2 (fr) * 2000-10-31 2002-05-10 Bayer Aktiengesellschaft Regulation de la glutathione-s-transferase humaine
AU2002229011A1 (en) * 2000-11-09 2002-05-21 Glaxo Group Limited Deaminase catalyzing the removal of the cyclopropyl moiety from abacavir-mp
EP1349934A2 (fr) 2000-11-20 2003-10-08 Diadexus, Inc. Compositions et methodes relatives a des genes et des proteines specifiques aux seins
AU2001297765A1 (en) * 2000-12-05 2002-10-21 Incyte Genomics, Inc. Ligases
JP2004524825A (ja) 2000-12-07 2004-08-19 ザイモジェネティクス，インコーポレイティド 脂肪細胞補体関連タンパク質ｚａｃｒｐ３ｘ２
AU2002227365A1 (en) 2000-12-07 2002-06-18 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
CA2439800A1 (fr) * 2000-12-14 2002-06-20 Pe Corporation (Ny) Proteines kinases humaines isolees, molecules d'acide nucleique codant des proteines kinases humaines et utilisations associees
US20020142376A1 (en) * 2000-12-20 2002-10-03 Gennady Merkulov Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
JP2004536566A (ja) 2000-12-22 2004-12-09 ブリストル−マイヤーズ　スクイブ　カンパニー 小腸において優先的に発現される新規なヒトロイシンリッチリピート含有タンパク質ｈｌｒｒｓｉ１
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US6423521B1 (en) * 2000-12-28 2002-07-23 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002053591A1 (fr) * 2000-12-30 2002-07-11 Lion Bioscience Ag Cofacteur de recepteur nucleaire mammalien cf12 et ses procedes d'utilisation
WO2002053754A2 (fr) * 2001-01-08 2002-07-11 Lexicon Genetics Incorporated Nouvelle protease humaine et polynucleotides codant cette derniere
JP2004524024A (ja) * 2001-01-30 2004-08-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 新規の核酸およびポリペプチド分子
EP1409536A2 (fr) * 2001-02-12 2004-04-21 Curagen Corporation Proteines, polynucleotides codant pour lesdites proteines et methodes d'utilisation desdites proteines
EP1637601A3 (fr) * 2001-02-21 2006-03-29 Curagen Corporation Protéines , polynucléotides codant pour ces protéines et procédés d'utilisation
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
AU2002250143A1 (en) * 2001-03-16 2002-10-03 Eli Lilly And Company Lp mammalian proteins; related reagents
CA2441378A1 (fr) 2001-03-22 2002-10-03 Dendreon San Diego Llc Molecules d'acide nucleique codant la serine protease cvsp14, polypeptides codes et procedes
WO2002077267A2 (fr) 2001-03-27 2002-10-03 Dendreon San Diego Llc Molecules d'acide nucleique codant une serine protease transmembranaire 9, polypeptides codes et procedes fondes sur ces derniers
US6913904B2 (en) * 2001-03-27 2005-07-05 Applera Corporation Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
ATE512216T1 (de) 2001-04-10 2011-06-15 Agensys Inc Nukleinsäure und dieser entsprechendes, 184p1e2 genanntes, für die behandlung und den nachweis von krebs geeignetes protein
EP2280030A3 (fr) 2001-04-10 2011-06-15 Agensys, Inc. Acides nucléiques et protéines correspondantes utiles dans la détection et le traitement des différents cancers
IL158293A0 (en) 2001-04-10 2004-05-12 Agensys Inc Nucleic acid and corresponding protein entitled 158p3d2 and pharmaceutical compositions containing the same
CA2483507A1 (fr) * 2001-04-24 2002-10-31 Isis Innovation Limited Enzyme et marqueur snp pour le depistage d'une maladie
CA2445309A1 (fr) * 2001-04-24 2002-11-07 Otsuka Pharmaceutical Co., Ltd. Peptide de liaison a des anticorps de la maladie de crohn et methode d'examen de ladite maladie
KR100781931B1 (ko) 2001-05-07 2007-12-04 시오노기세이야쿠가부시키가이샤 혈관신생 마커로서 사용되는 폴리펩티드 및 이의 ｄｎａ
AU2002314048A1 (en) * 2001-05-09 2002-11-18 Bayer Aktiengesellschaft Regulation of human phosphatidic acid phosphatase type 2c-like protein
WO2002092841A2 (fr) 2001-05-14 2002-11-21 Dendreon San Diego Llc Molecules d'acides nucleiques codant pour une serine protease transmembranaire 10, polypeptides codes et methodes associees
US7157558B2 (en) 2001-06-01 2007-01-02 Genentech, Inc. Polypeptide encoded by a polynucleotide overexpresses in tumors
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
AU2002311535A1 (en) * 2001-06-26 2003-01-08 Decode Genetics Ehf. Nucleic acids encoding protein kinases
GB2399085A (en) * 2001-08-02 2004-09-08 Aeomica Inc Human zinc finger containing gene MDZ12
AU2002359242A1 (en) * 2001-08-17 2003-04-22 Incyte Genomics, Inc. Intracellular signaling molecules
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
WO2003023063A1 (fr) * 2001-09-07 2003-03-20 Sankyo Company, Limited Methode d'estimation du risque d'apparition de diabetes
WO2003040369A2 (fr) * 2001-09-17 2003-05-15 Molecular Engines Laboratories Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2003025175A2 (fr) * 2001-09-17 2003-03-27 Molecular Engines Laboratories Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
JP2005534279A (ja) 2001-09-28 2005-11-17 ブリガム ヤング ユニバーシティ 新規なシクロオキシゲナーゼ変異体とその使用方法
EP1439225A4 (fr) 2001-10-04 2005-10-26 Kansai Tech Licensing Org Co Promoteur du gene dr5 et promoteur du gene siah-1
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003031607A1 (fr) * 2001-10-10 2003-04-17 Bayer Healthcare Ag Regulation de deshydrogenase/reductase des chaines courtes humaine
ATE364690T1 (de) 2001-11-09 2007-07-15 Proteologics Inc Posh nukleinsäure, polypeptide und darauf bezogene verfahren
AU2002365162A1 (en) 2001-11-14 2003-07-09 Northwestern University Self-assembly and mineralization of peptide-amphiphile nanofibers
CA2468145A1 (fr) * 2001-11-21 2003-05-30 Japan Science And Technology Agency Facteurs de transcription de gene de la choree de huntington
US7151162B2 (en) 2001-12-06 2006-12-19 The University Of Children's Hospital Of Both Cantons Of Basel Nuclear protein
AU2002339697A1 (en) * 2001-12-19 2003-06-30 Genset S.A. Gmg-5 polynucleotides and polypeptides and uses thereof
JP2003245084A (ja) 2001-12-20 2003-09-02 Morinaga Milk Ind Co Ltd 脳梁又は精子の形成不全の診断及び治療に有用な新規遺伝子、並びにその用途
DE10163467A1 (de) * 2001-12-21 2003-11-27 Axaron Bioscience Ag Protein 24B2 und zugrundliegende DNA-Sequenz
US6759222B2 (en) 2002-01-02 2004-07-06 Millennium Pharmaceuticals, Inc. 14815, a human kinase family member and uses therefor
WO2003057870A1 (fr) * 2002-01-07 2003-07-17 Bayer Healthcare Ag Proteine humaine analogue a la phosphatase de l'acide phosphatidique de type 2
WO2003060109A2 (fr) * 2002-01-15 2003-07-24 Bayer Healthcare Ag Regulation d'une subtilase humaine
AU2003205611A1 (en) * 2002-01-15 2003-07-30 Medigene Ag Dilated cardiomyopathy associated gene-2 (dcmag-2): a cytoplasmatic inducer of sarcomeric remodeling in cardiomyocytes
JPWO2003062429A1 (ja) * 2002-01-23 2005-05-26 山之内製薬株式会社 新規セリンプロテアーゼ
US7371719B2 (en) 2002-02-15 2008-05-13 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
EP1338609A1 (fr) * 2002-02-21 2003-08-27 MEMOREC Stoffel GmbH-Medizinisch-Molekulare Entwicklung, Köln Un outre récepteur KDR et son utilisation
CA2478271A1 (fr) * 2002-03-05 2003-09-18 Applera Corporation Proteines transporteuses humaines isolees, molecules d'acide nucleique codant celles-ci, et utilisations associees
GB2388113A (en) * 2002-03-06 2003-11-05 Oxford Glycosciences B-cell malignancy-associated protein
CA2992643C (fr) 2002-03-13 2019-06-18 Genomic Health, Inc. Profilage d'expression genique dans des tissus tumoraux ponctionnes
JP3949111B2 (ja) * 2002-03-19 2007-07-25 田辺製薬株式会社 新規ｇタンパク質共役型受容体およびその遺伝子
US7527935B2 (en) 2002-03-19 2009-05-05 Mitsubishi Tanabe Pharma Corporation G-protein coupled receptor having eicosanoid as ligand and gene thereof
GB0206684D0 (en) * 2002-03-21 2002-05-01 Babraham Inst Novel proteins
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US7329502B2 (en) 2002-04-25 2008-02-12 The United States Of America As Represented By The Department Of Health And Human Services ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
JP2004041003A (ja) * 2002-05-17 2004-02-12 Takeda Chem Ind Ltd 新規タンパク質、そのｄｎａおよびその用途
EP1507553A2 (fr) 2002-05-29 2005-02-23 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Proteines specifiques du pancreas
US7198899B2 (en) 2002-06-03 2007-04-03 Chiron Corporation Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers
PT1513934E (pt) 2002-06-06 2011-05-11 Oncotherapy Science Inc Genes e polip?ptidos relacionados com cancros de c?lon humanos
AU2003276679A1 (en) 2002-06-13 2003-12-31 Chiron Corporation Vectors for expression of hml-2 polypeptides
JPWO2004009626A1 (ja) * 2002-07-22 2005-11-17 アステラス製薬株式会社 慢性関節リウマチ関連新規遺伝子
AU2003256074B2 (en) 2002-08-14 2011-02-03 National Institute Of Advanced Industrial Science And Technology Novel N-acetylgalactosamine transferases and nucleic acids encoding the same
AU2003243151A1 (en) * 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
WO2004018518A1 (fr) * 2002-08-23 2004-03-04 Japan Science And Technology Agency Peptides antigeniques de tumeur cancereuse solide humains, polynucleotides codant pour ceux-ci et utilisation de ceux-ci
AU2003250989A1 (en) * 2002-08-27 2004-03-19 Epigenomics Ag Method and nucleic acids for the analysis of breast cell proliferative disorders
US7452969B2 (en) 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof
DE60325628D1 (de) 2002-09-30 2009-02-12 Oncotherapy Science Inc Gene und polypeptide in verbindung mit menschlichen pankreaskarzinomen
WO2004035823A2 (fr) * 2002-10-17 2004-04-29 Evotec Neurosciences Gmbh Utilisation diagnostique et therapeutique des gene et proteine ensadin-0625 destinee a des maladies neurodegeneratives
AU2002952216A0 (en) * 2002-10-23 2002-11-07 The Walter And Eliza Hall Institute Of Medical Research Novel therapeutic molecules
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
CA2506066A1 (fr) 2002-11-15 2004-06-03 Genomic Health, Inc. Etablissement de profils d'expressions genetique du cancer a recepteur de facteur de croissance epidermique positif
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2003287764B2 (en) * 2002-12-13 2010-01-21 The Walter And Eliza Hall Institute Of Medical Research A novel phosphoprotein
AU2002953341A0 (en) * 2002-12-13 2003-01-09 The Walter And Eliza Hall Institute Of Medical Research A novel phosphoprotein
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004070025A2 (fr) * 2003-02-05 2004-08-19 Juan Saus Nouvelles isoformes de la proteine liant l'antigene de goodpasture et troubles induits par une proteine incorrectement repliee
EP1445614A1 (fr) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Méthodes d'évaluation in vitro de l'état de progression d'un virus HIV chez un individu
US7074891B2 (en) * 2003-02-07 2006-07-11 Posco Leukocyte stimulating peptides
DK1597391T3 (da) 2003-02-20 2009-01-12 Genomic Health Inc Anvendelse af intron-RNA til måling af genekspression
EP1600458A4 (fr) * 2003-03-04 2006-10-25 Astellas Pharma Inc Nouveau gene associe a des conditions fibreuses
SI2248899T1 (sl) * 2003-03-19 2015-07-31 Biogen Ma Inc. Vezavni protein receptorja Nogo
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
EP1641810B2 (fr) 2003-06-24 2017-04-19 Genomic Health, Inc. Prediction de probabilite de la recurrence d'un cancer
DK1644858T3 (da) 2003-07-10 2018-01-22 Genomic Health Inc Funktionel beklædning med mindst et yderlag og en indermembran.
WO2005014818A1 (fr) 2003-08-08 2005-02-17 Perseus Proteomics Inc. Gene surexprime dans le cancer
US20050136434A1 (en) * 2003-08-12 2005-06-23 Mai Xu Isolated heat-inducible cell surface protein and hyperthermia-based tumor immunotargeting therapy
US20070178458A1 (en) * 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
TW200517503A (en) * 2003-09-10 2005-06-01 Japan Science & Tech Agency Group of genes differentially expressed in peripheral blood cells and diagnostic method and assay method using the same
CA2539715C (fr) * 2003-10-02 2015-02-24 Glaxosmithkline Biologicals S.A. Antigenes pertussis et leur utilisation dans la vaccination
US8329660B2 (en) 2003-10-03 2012-12-11 The Brigham And Women's Hospital, Inc. Tim-3 ligands and methods thereof
WO2005040791A2 (fr) * 2003-10-21 2005-05-06 Bayer Healthcare Ag Diagnostics et therapeutiques pour maladies liees au recepteur de peptides similaire a la somatostatine et a l'angiogenine (salpr)
US20050255560A1 (en) * 2003-11-21 2005-11-17 Zeren Gao Ztnf11, a tumor necrosis factor
CA2549164A1 (fr) * 2003-12-05 2005-06-23 Northwestern University Amphiphiles peptidiques a assemblage automatique et procedes associes d'administration de facteur de croissance
AU2004309396B2 (en) 2003-12-23 2010-05-13 Genomic Health, Inc. Universal amplification of fragmented RNA
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
AU2005227148B2 (en) * 2004-03-02 2010-11-11 The Johns Hopkins University Mutations of the PIK3CA gene in human cancers
TW200539890A (en) 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
WO2005090569A1 (fr) * 2004-03-24 2005-09-29 The Council Of The Queensland Institute Of Medical Research Cancer et acides nucleiques et proteines de testicule vsm1 et vsm2, et leurs utilisations
US9845344B2 (en) * 2004-03-30 2017-12-19 Hoba Therapeutics Aps Therapeutic use of a growth factor, NsG33
EP2947160B1 (fr) 2004-04-09 2017-07-12 Genomic Health, Inc. Marqueurs d'expression de genes permettant de predire une reponse a la chimiotherapie
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2005118832A2 (fr) * 2004-06-01 2005-12-15 Bayer Healthcare Ag Agents diagnostiques et therapeutiques pour des maladies associees a une proteine de type kinase regulee par serum/glucocorticoide (sgkl)
JP4960865B2 (ja) 2004-06-24 2012-06-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脱髄に関連する状態の処置
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
WO2006013661A1 (fr) * 2004-08-05 2006-02-09 Toagosei Co., Ltd. Peptide déterminant antigénique anticorps de la maladie de crohn et reactif pour test de la maladie de crohn
HUE051605T2 (hu) 2004-11-05 2021-03-01 Nsabp Found Inc Kemoterápiára adott válasz elõrejelzése génexpressziós markereket alkalmazva
EP1815014B1 (fr) 2004-11-05 2012-03-21 Genomic Health, Inc. Indicateurs moléculaires de pronostic du cancer du sein et prédiction de réponse du traitement
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1817340B1 (fr) 2004-11-12 2012-05-16 Xencor, Inc. Variants fc presentant une liaison modifiee au fcrn
CA2598251A1 (fr) 2005-03-04 2006-09-14 Northwestern University Epitopes angiogeniques de liaison a l'heparine, amphiphiles peptidiques, compositions auto-assemblees et procedes d'utilisation associes
US8497101B2 (en) * 2005-05-13 2013-07-30 Centre National De La Recherche Scientifique (Cnrs) Use of a new gene coding for a new member of the MCM2-8 family in pharmaceutical compositions
CA2614421A1 (fr) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Anticorps anti-sp35 et leurs utilisations
WO2007014338A2 (fr) * 2005-07-26 2007-02-01 Siemens Medical Solutions Diagnostics Polymorphismes de nucleotides uniques a susceptibilite par rapport a une maladie cardio-vasculaire
WO2007037601A1 (fr) * 2005-09-28 2007-04-05 Knu-Industry Cooperation Foundation Polypeptide inhibant la transmigration de leucocytes ou la croissance et/ou la métastase de cellules cancéreuses, et une protéine de fusion de celui-ci
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
DK1969003T3 (da) 2005-12-14 2010-12-13 Hermo Pharma Ltd Anvendelser af et neurotrofisk faktor-protein
CN101506376A (zh) * 2006-07-03 2009-08-12 埃克森希特医疗股份有限公司 前列腺特异性转录物及其在前列腺癌治疗和诊断中的应用
WO2008030559A2 (fr) * 2006-09-08 2008-03-13 Corixa Corporation Procédés, compositions, et kits de détection et de surveillance d'un cancer du colon
US8076295B2 (en) 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
US8999634B2 (en) * 2007-04-27 2015-04-07 Quest Diagnostics Investments Incorporated Nucleic acid detection combining amplification with fragmentation
GB0805159D0 (en) * 2008-03-19 2008-04-23 Sancho Madrid David Immune modulation via C-type lectin
UA103751C2 (ru) 2007-07-27 2013-11-25 Имматикс Биотекнолоджис Гмбх Иммуногенный пептид для иммунотерапии
US7863021B2 (en) * 2007-09-05 2011-01-04 Celera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
WO2009034661A1 (fr) * 2007-09-12 2009-03-19 Toppan Printing Co., Ltd. Procédé de diagnostic et induction d'une résistance à un virus
JP2011500047A (ja) 2007-10-17 2011-01-06 ウニベルシダ・ドゥ・コルドバ オルタナティブプロセシングにより産生されるヒトソマトスタチン受容体タイプ５のアイソフォーム、およびｐｃｒによるその検出のためのオリゴヌクレオチドペア
AU2008345242B2 (en) 2007-10-31 2014-02-27 Xencor, Inc. Fc variants with altered binding to FcRn
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
WO2009115612A1 (fr) * 2008-03-21 2009-09-24 Universiteit Hasselt Biomarqueurs de la polyarthrite rhumatoïde
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
CN102164611B (zh) 2008-07-24 2015-01-07 Ns基因公司 生长因子metrnl的治疗用途
PT2172211E (pt) * 2008-10-01 2015-03-09 Immatics Biotechnologies Gmbh Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
EP2358908B1 (fr) 2008-11-14 2014-01-08 Gen-Probe Incorporated Compositions et procédés pour la détection d'acide nucléique de campylobacter
WO2010062960A2 (fr) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center Méthodes de détermination d'une réceptivité à une thérapie par anti-tnfα lors d’une maladie intestinale inflammatoire
CA2745849A1 (fr) * 2008-12-09 2010-06-17 Alethia Biotherapeutics Inc. Nouveau variant retroviral endogene humain d'erv3 et utilisations de celui-ci pour diagnostiquer le cancer des ovaires
CA2758522A1 (fr) 2009-04-13 2010-10-21 Northwestern University Nouvelles structures peptidiques pour la regeneration des cartilages et procedes pour les utiliser
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2528615B1 (fr) 2010-01-27 2020-05-13 Massachusetts Institute of Technology Agents polypeptidiques techniques pour la neutralisation de la grippe à large spectre ciblée
CA2811644C (fr) 2010-09-29 2022-07-12 Agensys, Inc. Conjugues anticorps-medicaments (adc) se liant aux proteines 191p4d12
CN103269708A (zh) 2010-10-01 2013-08-28 Ns基因公司 镍纹蛋白用于治疗异常性疼痛、痛觉过敏、自发性疼痛和幻痛的用途
WO2012081040A1 (fr) * 2010-12-14 2012-06-21 Hananja Ehf. Activité biologique de la protéine placentaire 13
WO2013034157A1 (fr) 2011-09-05 2013-03-14 Nsgene A/S Traitement de l'allodynie, de l'hyperalgie, de la douleur spontanée et de la douleur illusionnelle
AR088699A1 (es) * 2011-11-09 2014-06-25 Sanofi Sa Diacilglicerol lipasa y usos de la misma
DK2844667T3 (en) 2012-04-30 2018-07-30 Biocon Ltd Targeted / immunomodulatory fusion proteins and methods for their preparation
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
WO2013173364A2 (fr) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Antagonistes de lingo-2 pour le traitement d'affections impliquant des neurones moteurs
WO2013174404A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
NZ707831A (en) 2012-11-13 2018-11-30 Astellas Pharma Inc Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (fr) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
RU2698975C2 (ru) 2013-03-12 2019-09-02 Биокон Лтд. Слитые иммуномодулирующие белки и способы их получения
US9023353B2 (en) 2013-03-13 2015-05-05 The Board Of Trustees Of The University Of Arkansas Anti-(+)—methamphetamine monoclonal antibodies
WO2014146672A1 (fr) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
AU2014241162A1 (en) 2013-03-27 2015-10-22 Cedars-Sinai Medical Center Mitigation and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways
PT3019619T (pt) 2013-07-11 2021-11-11 Modernatx Inc Composições que compreendem polinucleótidos sintéticos que codificam proteínas relacionadas com crispr e sgarn sintéticos e métodos de utilização
WO2015010108A1 (fr) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature de la voie de signalisation de tl1a (tnfsf15)
CN106163556B (zh) 2013-09-25 2024-04-09 西托姆克斯治疗公司 基质金属蛋白酶底物和其它可切割部分及其使用方法
JP6558699B2 (ja) * 2013-10-01 2019-08-14 国立大学法人三重大学 抗原提示を促進するエピトープ間配列を含むｔ細胞誘導ワクチン
CN106459153B (zh) 2014-01-31 2021-12-21 西托姆克斯治疗公司 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法
AU2016205197B2 (en) 2015-01-08 2021-10-21 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
WO2016201077A1 (fr) * 2015-06-12 2016-12-15 Emory University Compositions de croissance et de survie pour des cellules capables de produire des anticorps et procédés associés
EP3344776B1 (fr) 2015-09-04 2021-06-16 Synthetic Genomics, Inc. Micro-organisme recombinant algal de productivité accrue
CN118773299A (zh) 2016-03-17 2024-10-15 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
EP3436069A4 (fr) * 2016-03-29 2019-12-18 Valkyrie Therapeutics Inc. Modulation de l'entretien structural de l'expression du chromosome-1
US9611297B1 (en) 2016-08-26 2017-04-04 Thrasos Therapeutics Inc. Compositions and methods for the treatment of cast nephropathy and related conditions
US11125757B2 (en) 2017-05-26 2021-09-21 Emory University Methods of culturing and characterizing antibody secreting cells
EP3508499A1 (fr) 2018-01-08 2019-07-10 iOmx Therapeutics AG Anticorps ciblant et d'autres modulateurs d'un gène d'immunoglobuline associé à une résistance contre des réponses immunitaires antitumorales et leurs utilisations
US12257340B2 (en) 2018-12-03 2025-03-25 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
MX2021006429A (es) 2018-12-06 2021-07-15 Cytomx Therapeutics Inc Sustratos escindibles con matriz de metaloproteasa, serina o cisteína escindible con proteasa y métodos de uso de estos.
AU2020261435A1 (en) * 2019-04-26 2021-11-25 Sangamo Therapeutics, Inc. Engineering AAV
EP3994171A1 (fr) 2019-07-05 2022-05-11 iOmx Therapeutics AG Anticorps de liant à l'igc2 de l'igsf11 (vsig3) et leurs utilisations
US12280096B2 (en) 2021-07-12 2025-04-22 Penland Foundation Treatments of cancer using nitrous oxide and botulinum toxin
WO2021083958A1 (fr) * 2019-10-29 2021-05-06 Specialites Pet Food Nouveaux peptides induisant la satiété
JP7531931B2 (ja) * 2020-03-27 2024-08-13 ワンキュアジェン カンパニー，リミテッド Ｖｇｌｌ１ペプチドを含む癌治療用組成物
US20230212243A1 (en) * 2020-05-12 2023-07-06 Institut Curie Neoantigenic Epitopes Associated with SF3B1 Mutations
EP4150079A1 (fr) 2020-05-15 2023-03-22 Crispr Therapeutics AG Arn messager codant pour cas9 destiné à être utilisé dans des systèmes d'édition du génome
WO2022008027A1 (fr) 2020-07-06 2022-01-13 Iomx Therapeutics Ag Anticorps de liaison à l'igv d'igsf11 (vsig3) et leurs utilisations
CA3205170A1 (fr) * 2021-01-21 2022-07-28 Johannes Eduard Maria Antonius Debets Lymphocytes t destines a etre utilises en therapie
WO2022178318A1 (fr) * 2021-02-18 2022-08-25 Beren Therapeutics P.B.C. Méthodes de traitement de l'hypercholestérolémie familiale hétérozygote et homozygote avec des cyclodextrines
US20240158457A1 (en) * 2022-05-20 2024-05-16 Medikine, Inc. Interleukin-18 receptor binding polypeptides and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446240A (en) * 1981-01-30 1984-05-01 Nerenberg Samuel T Pancreas specific protein systems
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US6080540A (en) * 1990-04-20 2000-06-27 Cold Spring Harbor Laboratory Cloning of mammalian genes in microbial organisms and methods for pharmacological screening
WO1992009617A1 (fr) * 1990-11-26 1992-06-11 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Facteurs de transcription d'agression de cellules
US5721352A (en) * 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
US5840870A (en) * 1995-12-29 1998-11-24 Incyte Pharmaceuticals, Inc. Polynucleotides PANC1A and PANC1B associated with pancreatic cancer
WO1997007827A1 (fr) * 1995-08-22 1997-03-06 Thomas Jefferson University Gab1, QUI EST UNE PROTEINE SE LIANT A Grb2, ET COMPOSITIONS POUR PRODUIRE ET UTILISER CETTE PROTEINE
JP3462313B2 (ja) * 1995-08-24 2003-11-05 キッコーマン株式会社 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体ｄｎａ及び変異型ウリカーゼの製造法
US5998165A (en) * 1995-12-29 1999-12-07 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a protein associated with pancreatic cancer
EP0927046A4 (fr) * 1996-04-29 2002-10-02 Univ Johns Hopkins Med Regulateur de la degradation de l'arn chez les mammiferes induite par des transcrits non-sens
US6500934B1 (en) * 1996-07-24 2002-12-31 Michael Rush Lerner Bivalent agonists for G-protein coupled receptors
US5976834A (en) * 1997-01-09 1999-11-02 Smithkline Beecham Corporation cDNA clone HNFJD15 that encodes a novel human 7-transmembrane receptor
US5925521A (en) * 1997-03-31 1999-07-20 Incyte Pharmaceuticals, Inc. Human serine carboxypeptidase
CA2232743A1 (fr) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation Tl5, homologue tnf
EP0973898A2 (fr) * 1997-04-10 2000-01-26 Genetics Institute, Inc. MARQUEURS SECRETES DE SEQUENCE EXPRIMEE (sEST)
IT1291110B1 (it) * 1997-04-15 1998-12-29 Istituto Europ Di Oncologia S Interattori intracellulari e specificita' di legame del dominio eh
US5948641A (en) * 1997-05-29 1999-09-07 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a metal response element binding protein
EP1012292A1 (fr) * 1997-06-06 2000-06-28 Regeneron Pharmaceuticals, Inc. Element ntn-2 de la famille des ligands du tnf
AU9484398A (en) * 1997-09-17 1999-04-05 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US5932442A (en) * 1997-09-23 1999-08-03 Incyte Pharmaceuticals, Inc. Human regulatory molecules
US5972660A (en) * 1997-10-22 1999-10-26 Incyte Pharmaceuticals, Inc. Human hydroxypyruvate reductase
DE19818598A1 (de) * 1998-04-19 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Pankreasnormalgewebe
NZ507728A (en) * 1998-04-29 2002-06-28 Genesis Res & Dev Corp Ltd Information from a cDNA library created from keratinocytes, dermal papilla, neonatal foreskin fibroblast or embryonic skin cells is used to treating cancer, angiogenesis, skin inflammation, inflammatory diseases or stimulating keratinocyte growth
US6262249B1 (en) * 1998-06-23 2001-07-17 Chiron Corporation Pancreatic cancer genes
CA2296792A1 (fr) * 1999-02-26 2000-08-26 Genset S.A. Sequences marqueurs exprimees et proteines humaines codees

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE GENEMBL [online] 31 July 1998 (1998-07-31), STONE N.E. ET AL.: "Direct submission", XP002945285, Database accession no. AC004049 *

Also Published As

Publication number Publication date
CA2398411A1 (fr) 2001-08-02
WO2001055307A3 (fr) 2002-01-10
WO2001055318A2 (fr) 2001-08-02
WO2001055315A2 (fr) 2001-08-02
WO2001055350A8 (fr) 2001-09-07
WO2001055343A1 (fr) 2001-08-02
WO2001055325A8 (fr) 2001-12-13
WO2001055200A8 (fr) 2001-09-07
WO2001055324A8 (fr) 2001-09-07
WO2001055205A1 (fr) 2001-08-02
WO2001055327A8 (fr) 2001-09-07
WO2001055202A1 (fr) 2001-08-02
WO2001055310A3 (fr) 2001-12-27
WO2001055319A3 (fr) 2002-02-21
WO2001055314A3 (fr) 2002-05-02
WO2001055302A2 (fr) 2001-08-02
WO2001055324A2 (fr) 2001-08-02
CA2395738A1 (fr) 2002-08-02
WO2001054733A8 (fr) 2001-09-07
WO2001055202A8 (fr) 2001-09-07
CA2392428A1 (fr) 2001-08-02
WO2001055308A8 (fr) 2001-09-07
WO2001055309A2 (fr) 2001-08-02
WO2001055308A3 (fr) 2002-07-04
WO2001055304A2 (fr) 2001-08-02
CA2392398A1 (fr) 2001-08-02
WO2001055204A8 (fr) 2001-09-07
WO2001055302A8 (fr) 2001-09-07
WO2001055301A3 (fr) 2009-06-04
WO2001055355A8 (fr) 2001-09-07
WO2001055207A8 (fr) 2001-09-07
WO2001055321A8 (fr) 2001-09-07
WO2001055203A1 (fr) 2001-08-02
WO2001055316A2 (fr) 2001-08-02
WO2001055163A1 (fr) 2001-08-02
WO2001055364A2 (fr) 2001-08-02
WO2001055311A8 (fr) 2001-09-07
WO2001055448A8 (fr) 2001-09-07
WO2001055204A1 (fr) 2001-08-02
AU4141101A (en) 2001-08-20
CA2393002A1 (fr) 2001-08-02
AU2001241412A1 (en) 2001-08-07
WO2001055201A1 (fr) 2001-08-02
AU2001241408A1 (en) 2001-08-07
WO2001055322A3 (fr) 2002-07-04
WO2001055208A8 (fr) 2001-09-07
WO2001055312A3 (fr) 2002-03-14
WO2001055311A3 (fr) 2002-07-04
WO2001055350A1 (fr) 2001-08-02
WO2001055304A8 (fr) 2001-09-07
WO2001054474A2 (fr) 2001-08-02
AU2001250770A1 (en) 2001-08-07
CA2395872A1 (fr) 2001-08-02
WO2001055173A2 (fr) 2001-08-02
WO2001054473A8 (fr) 2001-09-07
CA2395816A1 (fr) 2001-08-02
CA2397407A1 (fr) 2001-08-02
CA2395787A1 (fr) 2001-08-02
CA2392450A1 (fr) 2001-08-16
AU2001241409A1 (en) 2001-08-07
WO2001055316A8 (fr) 2001-09-07
WO2001055321A2 (fr) 2001-08-02
WO2001055315A3 (fr) 2002-02-07
WO2001055364A3 (fr) 2002-07-04
WO2001057182A3 (fr) 2002-03-28
WO2001055328A2 (fr) 2001-08-02
WO2001055387A1 (fr) 2001-08-02
WO2001055327A3 (fr) 2002-02-28
WO2001055322A2 (fr) 2001-08-02
WO2001055327A2 (fr) 2001-08-02
WO2001055303A2 (fr) 2001-08-02
WO2001055309A3 (fr) 2002-07-18
CA2392751A1 (fr) 2001-08-02
WO2001055322A8 (fr) 2001-09-07
WO2001055208A1 (fr) 2001-08-02
WO2001055447A1 (fr) 2001-08-02
WO2001055314A2 (fr) 2001-08-02
WO2001055447A8 (fr) 2001-09-07
AU2001241410A1 (en) 2001-08-07
WO2001055367A1 (fr) 2001-08-02
WO2001055303A3 (fr) 2001-12-20
WO2001055308A2 (fr) 2001-08-02
WO2001055315A8 (fr) 2001-09-07
WO2001055203A8 (fr) 2001-09-07
CA2393912A1 (fr) 2001-08-02
CA2395699A1 (fr) 2001-08-02
WO2001055368A1 (fr) 2001-08-02
WO2001055324A3 (fr) 2002-01-24
WO2001059064A2 (fr) 2001-08-16
CA2395403A1 (fr) 2001-08-02
CA2395654A1 (fr) 2001-08-02
WO2001055304A3 (fr) 2002-07-18
WO2001055163A8 (fr) 2001-09-07
WO2001055319A2 (fr) 2001-08-02
CA2394841A1 (fr) 2001-08-02
WO2001055343A8 (fr) 2001-09-07
CA2395398A1 (fr) 2001-08-02
CA2397839A1 (fr) 2001-08-02
AU4313701A (en) 2001-08-14
CA2392757A1 (fr) 2001-08-02
CA2395858A1 (fr) 2001-08-02
CA2395724A1 (fr) 2001-08-02
WO2001055367A8 (fr) 2001-12-20
WO2001055201A8 (fr) 2001-09-07
WO2001055207A1 (fr) 2001-08-02
AU2001241405A1 (en) 2001-08-07
CA2392422A1 (fr) 2001-08-02
WO2001055307A8 (fr) 2001-09-07
CA2393652A1 (fr) 2001-08-02
AU2001241406A1 (en) 2001-08-07
WO2001055301A8 (fr) 2001-09-07
WO2001055328A8 (fr) 2001-09-07
WO2001055355A1 (fr) 2001-08-02
CA2395827A1 (fr) 2001-08-02
CA2395671A1 (fr) 2001-08-02
CA2392438A1 (fr) 2001-08-02
WO2001055206A1 (fr) 2001-08-02
WO2001055312A8 (fr) 2001-09-07
CA2398877A1 (fr) 2001-08-09
WO2001055325A3 (fr) 2002-07-04
CA2395729A1 (fr) 2001-08-02
CA2395849A1 (fr) 2001-08-02
WO2001055310A8 (fr) 2001-09-07
AU2001241418A1 (en) 2001-08-07
WO2001055200A1 (fr) 2001-08-02
WO2001055320A3 (fr) 2002-04-11
WO2001055206A8 (fr) 2001-12-13
WO2001055314A8 (fr) 2001-09-07
CA2395885A1 (fr) 2001-08-02
WO2001055387A8 (fr) 2001-12-06
AU2001241414A1 (en) 2001-08-07
WO2001054733A1 (fr) 2001-08-02
CA2395693A1 (fr) 2001-08-02
AU2001241416A1 (en) 2001-08-07
WO2001055307A2 (fr) 2001-08-02
CA2395295A1 (fr) 2001-08-02
CA2395178A1 (fr) 2001-08-02
WO2001055323A8 (fr) 2001-09-07
WO2001057182A2 (fr) 2001-08-09
AU2001241415A1 (en) 2001-08-07
WO2001055320A2 (fr) 2001-08-02
WO2001055321A3 (fr) 2002-07-04
CA2395734A1 (fr) 2001-08-02
WO2001054474A8 (fr) 2001-12-20
AU2001241417A1 (en) 2001-08-07
WO2001055318A3 (fr) 2002-07-04
CA2394039A1 (fr) 2001-08-02
WO2001055173A8 (fr) 2001-11-29
WO2001055302A3 (fr) 2002-02-14
WO2001055323A3 (fr) 2002-05-10
WO2001055325A2 (fr) 2001-08-02
WO2001055310A2 (fr) 2001-08-02
AU2001241413A1 (en) 2001-08-07
CA2393618A1 (fr) 2001-08-02
WO2001055364A8 (fr) 2001-09-07
WO2001055448A1 (fr) 2001-08-02
CA2395666A1 (fr) 2001-08-02
WO2001055368A8 (fr) 2001-09-07
WO2001055318A8 (fr) 2001-09-07
WO2001055328A3 (fr) 2002-07-04
WO2001055311A2 (fr) 2001-08-02
WO2001055301A2 (fr) 2001-08-02
WO2001055320A8 (fr) 2001-09-07
WO2001055205A8 (fr) 2001-12-13
WO2001055309A8 (fr) 2001-09-07
WO2001055312A2 (fr) 2001-08-02
WO2001055319A8 (fr) 2001-09-07
WO2001054473A2 (fr) 2001-08-02
WO2001055303A8 (fr) 2001-09-07
WO2001055323A2 (fr) 2001-08-02
AU2001241407A1 (en) 2001-08-07
WO2001055316A3 (fr) 2002-04-11

Similar Documents

Publication Publication Date Title
WO2001059064A3 (fr) Acides nucleiques, proteines et anticorps
WO2001059063A3 (fr) Acides nucleiques, proteines et anticorps
WO2001055317A8 (fr) Acides nucleiques, proteines et anticorps
WO2002000677A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055300A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055313A3 (fr) Acides nucleiques, proteines et anticorps
WO2001055162A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055329A3 (fr) Acides nucleiques, proteines et anticorps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2392450

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001912656

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001912656

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001912656

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)